Cargando…

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor antagonist (5HT3RA), corticosteroid, and dopamine antag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Winnie, Li, Leung, Lau, Thomas KH, Lai, Kwai T, Chan, Vicky TC, Wong, Kwan H, Yip, Christopher CH, Pang, Elizabeth, Cheung, Maggie, Chan, Vivian, Kwok, Carol CH, Suen, Joyce JS, Mo, Frankie KF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330523/ https://www.ncbi.nlm.nih.gov/pubmed/33710814 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0241

Ejemplares similares

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
por: Yeo, Winnie, et al.
Publicado: (2020)

A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
por: Yeo, Winnie, et al.
Publicado: (2020)

Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
por: Yeo, Winnie, et al.
Publicado: (2021)

Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy
por: Yeo, Winnie, et al.
Publicado: (2018)

Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy
por: Yang, Chan-Keng, et al.
Publicado: (2016)

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC
por: Matsuura, Kazuo, et al.
Publicado: (2022)

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
por: Li, Leung, et al.
Publicado: (2017)

Antiemetics and Cancer Chemotherapy
por: Wilkinson, P.W.
Publicado: (1983)

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic
por: Shetti, Akshaya N., et al.
Publicado: (2014)

The effect of antiemetics in childhood gastroenteritis
por: Das, Jai K, et al.
Publicado: (2013)

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
por: Yeo, Winnie, et al.
Publicado: (2015)

Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide
por: Suehiro, Marii, et al.
Publicado: (2021)

Appropriate prescribing of antiemetics with oral oncolytic therapy: a single center experience
por: Suen, Connie T., et al.
Publicado: (2019)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - A comparative evaluation
por: Gupta, Kumkum, et al.
Publicado: (2014)

Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada
por: Grant, Robert C., et al.
Publicado: (2020)

Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2020)

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients
por: Kaushal, Pulkit, et al.
Publicado: (2015)

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
por: Vaz-Luis, Ines, et al.
Publicado: (2020)

International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study
por: Chan, Stephen L., et al.
Publicado: (2014)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Cyclophosphamide/doxorubicin: Prolongation of SARS-CoV-2 infection: case report
Publicado: (2021)

Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy
por: Javed, Aneeqa, et al.
Publicado: (2022)

Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
por: McMillan, C., et al.
Publicado: (1991)

Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline
por: Patil, Vijay, et al.
Publicado: (2016)

Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors
por: Yeo, Winnie, et al.
Publicado: (2020)

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2019)

Use of antiemetics in children with acute gastroenteritis: Are they safe and effective?
por: Manteuffel, Jacob
Publicado: (2009)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

Analysis of Antiemetic Use After Initiation of Hormone Therapy
por: Rahbek, Martin Torp, et al.
Publicado: (2022)

Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent
por: Solanki, Sohel, et al.
Publicado: (2022)

Veneral Prophylaxis Post Hoc
Publicado: (1913)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

Increasing pacemaker lead impedance and pacing threshold after initiation of chemotherapy with doxorubicin and cyclophosphamide
por: Varela, Daniel L., et al.
Publicado: (2022)

Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_520q570jd079e97k7bhtc9bcri